Na + /H + Exchanger 1, a Potential Therapeutic Drug Target for Cardiac Hypertrophy and Heart Failure.
Huiting XiaAqeela ZahraMeng JiaQun WangYunfu WangSusan L CampbellJianping WuPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Cardiac hypertrophy is defined as increased heart mass in response to increased hemodynamic requirements. Long-term cardiac hypertrophy, if not counteracted, will ultimately lead to heart failure. The incidence of heart failure is related to myocardial infarction, which could be salvaged by reperfusion and ultimately invites unfavorable myocardial ischemia-reperfusion injury. The Na + /H + exchangers (NHEs) are membrane transporters that exchange one intracellular proton for one extracellular Na + . The first discovered NHE isoform, NHE1, is expressed almost ubiquitously in all tissues, especially in the myocardium. During myocardial ischemia-reperfusion, NHE1 catalyzes increased uptake of intracellular Na + , which in turn leads to Ca 2+ overload and subsequently myocardial injury. Numerous preclinical research has shown that NHE1 is involved in cardiac hypertrophy and heart failure, but the exact molecular mechanisms remain elusive. The objective of this review is to demonstrate the potential role of NHE1 in cardiac hypertrophy and heart failure and investigate the underlying mechanisms.
Keyphrases
- heart failure
- left ventricular
- atrial fibrillation
- cardiac resynchronization therapy
- acute heart failure
- ischemia reperfusion injury
- acute myocardial infarction
- oxidative stress
- emergency department
- gene expression
- fluorescent probe
- risk assessment
- cell therapy
- living cells
- electronic health record
- mesenchymal stem cells
- sensitive detection
- adverse drug
- molecular dynamics